Doxofylline: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Protected "Doxofylline": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(No difference)

Latest revision as of 20:14, 18 August 2015

Doxofylline
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
UNII
KEGG
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC11H14N4O4
Molar mass266.25 g/mol
3D model (JSmol)
  (verify)

WikiDoc Resources for Doxofylline

Articles

Most recent articles on Doxofylline

Most cited articles on Doxofylline

Review articles on Doxofylline

Articles on Doxofylline in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Doxofylline

Images of Doxofylline

Photos of Doxofylline

Podcasts & MP3s on Doxofylline

Videos on Doxofylline

Evidence Based Medicine

Cochrane Collaboration on Doxofylline

Bandolier on Doxofylline

TRIP on Doxofylline

Clinical Trials

Ongoing Trials on Doxofylline at Clinical Trials.gov

Trial results on Doxofylline

Clinical Trials on Doxofylline at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Doxofylline

NICE Guidance on Doxofylline

NHS PRODIGY Guidance

FDA on Doxofylline

CDC on Doxofylline

Books

Books on Doxofylline

News

Doxofylline in the news

Be alerted to news on Doxofylline

News trends on Doxofylline

Commentary

Blogs on Doxofylline

Definitions

Definitions of Doxofylline

Patient Resources / Community

Patient resources on Doxofylline

Discussion groups on Doxofylline

Patient Handouts on Doxofylline

Directions to Hospitals Treating Doxofylline

Risk calculators and risk factors for Doxofylline

Healthcare Provider Resources

Symptoms of Doxofylline

Causes & Risk Factors for Doxofylline

Diagnostic studies for Doxofylline

Treatment of Doxofylline

Continuing Medical Education (CME)

CME Programs on Doxofylline

International

Doxofylline en Espanol

Doxofylline en Francais

Business

Doxofylline in the Marketplace

Patents on Doxofylline

Experimental / Informatics

List of terms related to Doxofylline

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Doxofylline (INN), (also known as doxophylline) is a xanthine derivative drug used in the treatment of asthma.[1]

It has antitussive[citation needed] and bronchodilator[2] effects, and acts as a phosphodiesterase inhibitor.[3]

In animal and human studies, it has shown similar efficacy to theophylline but with significantly fewer side effects.[4]

Unlike other xanthines, doxofylline lacks any significant affinity for adenosine receptors and does not produce stimulant effects. This suggests that its antiasthmatic effects are mediated by another mechanism, perhaps its actions on phosphodiesterase.[1]

References

  1. 1.0 1.1 Cirillo R, Barone D, Franzone JS (1988). "Doxofylline, an antiasthmatic drug lacking affinity for adenosine receptors". Arch Int Pharmacodyn Ther. 295: 221–37. PMID 3245738.
  2. Poggi R, Brandolese R, Bernasconi M, Manzin E, Rossi A (October 1989). "Doxofylline and respiratory mechanics. Short-term effects in mechanically ventilated patients with airflow obstruction and respiratory failure". Chest. 96 (4): 772–8. doi:10.1378/chest.96.4.772. PMID 2791671.
  3. Dini FL, Cogo R (2001). "Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects". Curr Med Res Opin. 16 (4): 258–68. doi:10.1185/030079901750120196. PMID 11268710.
  4. Sankar J, Lodha R, Kabra SK (March 2008). "Doxofylline: The next generation methylxanthine". Indian J Pediatr. 75 (3): 251–4. doi:10.1007/s12098-008-0054-1. PMID 18376093.
  • Dali Shukla, Subhashis Chakraborty, Sanjay Singh & Brahmeshwar Mishra. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy. 2009; 10(14): 2343-2356, DOI 10.1517/14656560903200667, PMID 19678793

Template:Asthma and copd rx Template:Phosphodiesterase inhibitors